News
Multiply Labs Secures $75 Million Series B for Robotic Biomanufacturing
FundingOctober 14, 2026, 9:38 am
Multiply Labs secured $75 million in Series B funding. This propels its total capital past $100 million. The physical AI leader automates complex biomanufacturing processes. This critical round, spearheaded by NantWorks and joined by major new investors, scales robotic platforms for advanced medicines. The technology significantly cuts production costs. It boosts throughput for vital therapies like cell and gene treatments. This accelerates drug delivery to patients. It signals a pivotal shift in pharmaceutical innovation and accessibility.
Multiply Labs has announced a substantial $75 million Series B funding round. This significant capital injection pushes the company’s total funding beyond $100 million since its 2016 inception. The investment will accelerate the deployment of its advanced robotic biomanufacturing platform. This represents a major leap for medicine production.
NantWorks, led by Dr. Patrick Soon-Shiong, spearheaded the financing. This leadership signals strong confidence in Multiply Labs’ vision. New strategic investors joined the round. AstraZeneca, Lingotto, Teradyne, and Strange Ventures contributed. Returning investors also participated. Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund reaffirmed their commitment. This broad investor base underscores the technology's industry-wide appeal.
Multiply Labs is at the forefront of physical AI. It automates some of medicine’s most intricate manufacturing processes. Its core innovation centers on robotic clusters. These systems precisely execute complex biologic manufacturing. They represent a fundamental shift from traditional methods.
Biomanufacturing faces immense challenges. Manual processes are often slow and error-prone. They drive up costs. They limit patient access to life-saving therapies. Multiply Labs’ solution directly addresses these critical bottlenecks. Its automated systems offer unprecedented precision and scalability.
The company's robotic clusters deliver transformative benefits. They slash the cost per dose by up to 74 percent. This dramatically improves affordability for advanced treatments. Throughput increases by a staggering 100 times compared to manual operations. This allows for rapid production scaling. More patients can receive therapies faster.
A key advantage lies in integration. The robotic systems are designed for seamless adoption. They fit into existing manufacturing facilities. Companies avoid costly new construction. They bypass disruptive changes to validated production practices. This accelerates implementation for pharmaceutical partners.
Initially, Multiply Labs focused on cell and gene therapies. These treatments are highly complex. Their manufacturing demands extreme precision. The company is now expanding its scope. Its technology will benefit antibodies, viral vectors, and mRNA production. This broadens its impact across the biologics landscape.
The business model is distinct. Pharmaceutical and biologics companies directly own and operate the platform. Multiply Labs is not an outsourced manufacturing service. This empowers drug developers. They maintain control over their proprietary processes. This model fosters closer collaboration and deeper integration.
The newly secured funding has clear objectives. A primary goal is expanding manufacturing capacity. This meets growing demand for automated solutions. It accelerates the product roadmap. New features and capabilities will emerge. The company also plans to grow its expert teams. Engineering, regulatory, and commercial departments will see expansion. This ensures robust support and market penetration.
The biopharmaceutical industry is evolving rapidly. Artificial intelligence designs increasingly complex therapies. Manufacturing capabilities struggle to keep pace. This creates a significant gap. Multiply Labs aims to close this gap. Its physical AI platform bridges the divide between drug discovery and patient delivery.
The involvement of major pharmaceutical entities like AstraZeneca is crucial. It validates the technology. It signals a strategic imperative for the industry. Large players recognize the need for manufacturing transformation. Automation is not just an advantage; it is a necessity.
Manufacturing cell therapies presents particular difficulties. Every step demands adherence to Good Manufacturing Practices (GMP). This ensures product quality and patient safety. Multiply Labs’ robotic systems ensure this consistency. They minimize human error. They uphold stringent regulatory standards.
Robotics transformed other industries. Automotive manufacturing saw revolution. Semiconductor production achieved new efficiencies. Biomanufacturing stands poised for a similar transformation. Manual, labor-intensive processes will yield to precise, scalable production systems. This vision guides Multiply Labs' innovation.
The future of medicine hinges on scalable production. Advanced therapies promise cures for previously untreatable diseases. Without efficient manufacturing, these promises remain unfulfilled. Multiply Labs provides a critical infrastructure solution. It enables mass production of personalized and complex medicines.
This funding round is more than just financial news. It represents a commitment to patient access. It signals a belief in technological advancement. It underscores the vital role of automation in modern healthcare. Multiply Labs is not just building robots. It is building the future of medicine production.
Multiply Labs has announced a substantial $75 million Series B funding round. This significant capital injection pushes the company’s total funding beyond $100 million since its 2016 inception. The investment will accelerate the deployment of its advanced robotic biomanufacturing platform. This represents a major leap for medicine production.
NantWorks, led by Dr. Patrick Soon-Shiong, spearheaded the financing. This leadership signals strong confidence in Multiply Labs’ vision. New strategic investors joined the round. AstraZeneca, Lingotto, Teradyne, and Strange Ventures contributed. Returning investors also participated. Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund reaffirmed their commitment. This broad investor base underscores the technology's industry-wide appeal.
Multiply Labs is at the forefront of physical AI. It automates some of medicine’s most intricate manufacturing processes. Its core innovation centers on robotic clusters. These systems precisely execute complex biologic manufacturing. They represent a fundamental shift from traditional methods.
Biomanufacturing faces immense challenges. Manual processes are often slow and error-prone. They drive up costs. They limit patient access to life-saving therapies. Multiply Labs’ solution directly addresses these critical bottlenecks. Its automated systems offer unprecedented precision and scalability.
The company's robotic clusters deliver transformative benefits. They slash the cost per dose by up to 74 percent. This dramatically improves affordability for advanced treatments. Throughput increases by a staggering 100 times compared to manual operations. This allows for rapid production scaling. More patients can receive therapies faster.
A key advantage lies in integration. The robotic systems are designed for seamless adoption. They fit into existing manufacturing facilities. Companies avoid costly new construction. They bypass disruptive changes to validated production practices. This accelerates implementation for pharmaceutical partners.
Initially, Multiply Labs focused on cell and gene therapies. These treatments are highly complex. Their manufacturing demands extreme precision. The company is now expanding its scope. Its technology will benefit antibodies, viral vectors, and mRNA production. This broadens its impact across the biologics landscape.
The business model is distinct. Pharmaceutical and biologics companies directly own and operate the platform. Multiply Labs is not an outsourced manufacturing service. This empowers drug developers. They maintain control over their proprietary processes. This model fosters closer collaboration and deeper integration.
The newly secured funding has clear objectives. A primary goal is expanding manufacturing capacity. This meets growing demand for automated solutions. It accelerates the product roadmap. New features and capabilities will emerge. The company also plans to grow its expert teams. Engineering, regulatory, and commercial departments will see expansion. This ensures robust support and market penetration.
The biopharmaceutical industry is evolving rapidly. Artificial intelligence designs increasingly complex therapies. Manufacturing capabilities struggle to keep pace. This creates a significant gap. Multiply Labs aims to close this gap. Its physical AI platform bridges the divide between drug discovery and patient delivery.
The involvement of major pharmaceutical entities like AstraZeneca is crucial. It validates the technology. It signals a strategic imperative for the industry. Large players recognize the need for manufacturing transformation. Automation is not just an advantage; it is a necessity.
Manufacturing cell therapies presents particular difficulties. Every step demands adherence to Good Manufacturing Practices (GMP). This ensures product quality and patient safety. Multiply Labs’ robotic systems ensure this consistency. They minimize human error. They uphold stringent regulatory standards.
Robotics transformed other industries. Automotive manufacturing saw revolution. Semiconductor production achieved new efficiencies. Biomanufacturing stands poised for a similar transformation. Manual, labor-intensive processes will yield to precise, scalable production systems. This vision guides Multiply Labs' innovation.
The future of medicine hinges on scalable production. Advanced therapies promise cures for previously untreatable diseases. Without efficient manufacturing, these promises remain unfulfilled. Multiply Labs provides a critical infrastructure solution. It enables mass production of personalized and complex medicines.
This funding round is more than just financial news. It represents a commitment to patient access. It signals a belief in technological advancement. It underscores the vital role of automation in modern healthcare. Multiply Labs is not just building robots. It is building the future of medicine production.